1. Home
  2. QLGN vs CHNR Comparison

QLGN vs CHNR Comparison

Compare QLGN & CHNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • CHNR
  • Stock Information
  • Founded
  • QLGN 1996
  • CHNR N/A
  • Country
  • QLGN United States
  • CHNR China
  • Employees
  • QLGN N/A
  • CHNR N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • CHNR Precious Metals
  • Sector
  • QLGN Health Care
  • CHNR Basic Materials
  • Exchange
  • QLGN Nasdaq
  • CHNR Nasdaq
  • Market Cap
  • QLGN 4.8M
  • CHNR 5.3M
  • IPO Year
  • QLGN N/A
  • CHNR 1995
  • Fundamental
  • Price
  • QLGN $5.02
  • CHNR $4.96
  • Analyst Decision
  • QLGN
  • CHNR
  • Analyst Count
  • QLGN 0
  • CHNR 0
  • Target Price
  • QLGN N/A
  • CHNR N/A
  • AVG Volume (30 Days)
  • QLGN 4.8M
  • CHNR 289.1K
  • Earning Date
  • QLGN 11-13-2025
  • CHNR 11-11-2025
  • Dividend Yield
  • QLGN N/A
  • CHNR N/A
  • EPS Growth
  • QLGN N/A
  • CHNR N/A
  • EPS
  • QLGN N/A
  • CHNR N/A
  • Revenue
  • QLGN N/A
  • CHNR N/A
  • Revenue This Year
  • QLGN N/A
  • CHNR N/A
  • Revenue Next Year
  • QLGN N/A
  • CHNR N/A
  • P/E Ratio
  • QLGN N/A
  • CHNR N/A
  • Revenue Growth
  • QLGN N/A
  • CHNR N/A
  • 52 Week Low
  • QLGN $1.61
  • CHNR $3.16
  • 52 Week High
  • QLGN $10.45
  • CHNR $9.04
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 61.57
  • CHNR 61.22
  • Support Level
  • QLGN $4.91
  • CHNR $4.81
  • Resistance Level
  • QLGN $6.16
  • CHNR $5.26
  • Average True Range (ATR)
  • QLGN 1.00
  • CHNR 0.52
  • MACD
  • QLGN 0.06
  • CHNR -0.02
  • Stochastic Oscillator
  • QLGN 43.01
  • CHNR 29.98

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.

About CHNR China Natural Resources Inc.

China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.

Share on Social Networks: